MedTrace Logo

Pilot-Scale Clinical Trials of Kibow Biotics® in Chronic Kidney Failure

NCT00760162 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2019-08-20

No results posted yet for this study

Summary

The bowel can serve as a complement to the kidneys' excretory function

A specifically formulated probiotic product comprised of defined and tested microbial strains may afford renoprotection in what has been called "enteric dialysis"® Confirm the alleviation of uremic syndrome hypothesis Determine the outcome of probiotics treatment Confirm U.S. FDA's Generally Recognized As Safe (GRAS) status - if needed

Conditions

  • Chronic Kidney Failure

Sponsors & Collaborators

  • Kibow Pharma

    lead INDUSTRY

Principal Investigators

  • Eli A Friedman, MD · Downstate Medical Center - State University of New York, Brooklyn, NY

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2009-07-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00760162 on ClinicalTrials.gov